Keywords
Cannabis sativa
Nonalcoholic fatty liver disease (NAFLD)
Fatty liver
Hepatic steatosis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the role of cannabidiol (CBD) as a possible therapeutic tool for hepatic steatosis. Literature review: The liver is a multifunctional metabolic organ that performs a series of metabolic processes, such as: bile secretion, filtration of toxic substances from the body, storage of vitamins, regulation of blood flow, synthesis of essential substances and metabolism of carbohydrates, lipids and proteins. When developing a picture of hepatic steatosis, the liver has its functions directly impaired, due to the accumulation of fat. In this line, Cannabidiol emerges as a promising therapeutic tool in the treatment of steatosis, since CBD has the ability to modulate lipid metabolism, perform anti-inflammatory and antioxidant action, hepatoprotective effect and possible anticancer potential. Final considerations: Experimental studies suggest that CBD can reduce fat deposition in the liver, a hallmark of hepatic steatosis, attenuate oxidative stress and modulate inflammatory pathways associated with the progression of non-alcoholic fatty liver disease. However, more clinical research is still needed to correlate the dosage and adverse effects of CBD in the management of hepatic steatosis.
References
ARAÚJO M, et al. Mecanismo de ação dos canabinoides: visão geral. Revista Brasileira de Terapias Paliativas, 2023; Supl. 2, p. S109-S113.
ARRUDA VM. Estresse oxidativo, inflamação e apoptose em modelo in vitro da doença hepática gordurosa associada ao metabolismo. Dissertação (Mestrado em Biotecnologia) - Universidade Federal de Uberlândia, Patos de Minas, 2023; p79.
BARBOSA CA, et al. Revisão da anatomia fígado, vesícula e vias biliares. ONLINE: Editora Científica Digital, 2023; p. 309-321.
BYRNE CD, TARGHER G. NAFLD: a multisystem disease. Journal of hepatology, 2015; p. S47-S64.
CASTILLO-ARELLANO J, et al. The polypharmacological effects of cannabidiol. Molecules, 2023; p. 3271.
CHALASANI N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; p. 328-357.
CINTRA DE. Integração entre vias metabolicas e inflamatorias durante a esteatose hepatica induzida por dieta hiperlipidica. Tese de Doutorado (Doutorado em Clínica Médica) - Universidade Estadual de Campinas, São Paulo, 2008; 100p.
CZECH MP. Ação e resistência à insulina na obesidade e diabetes tipo 2. Nature medicine, 2017; p. 804-814.
DE TERNAY J, et al. Therapeutic prospects of cannabidiol for alcohol use disorder and~9 alcohol-related damages on the liver and the brain. Frontiers in pharmacology, 2019; p. 627.
DEGRAVE V, et al. Effects of full-spectrum cannabis oil with a cannabidiol: tetrahydrocannabinol 2: 1 ratio on the mechanisms involved in hepatic steatosis and oxidative stress in rats fed a sucrose-rich diet. Medical Cannabis and Cannabinoids, 2023; p. 170-183.
DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. New England Journal of Medicine, 2017; p. 2063-2072.
ESTES C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018; p. 123-133.
FREITAS MC, et al. Resistência à insulina associado à obesidade: efeitos anti-inflamatórios do exercício físico. Revista Brasileira de Ciência e Movimento, 2014; p. 139-147.
GIESTAS S, et al. Doença hepática e diabetes mellitus–uma relação bi-direcional. Revista Portuguesa de Diabetes, 2015; p. 158-166.
GINÈS P, et al. Liver cirrhosis. The Lancet, 2021; p.1359-1376.
HUANG Y, et al. Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway. Journal of Cellular Physiology, 2019; p. 21224–21234.
LESSA MA, et al. Derivados canabinoides e o tratamento farmacológico da dor. Revista Dor, São Paulo, 2022; p. 9-15.
MARINHO AMN, SILVA-NETO RWG. Anti-inflammatory effects of cannabinoids. Brazilian Journal of Pain, 2023; p. 31–37.
MANTOVANI A. Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. J Clin Transl Hepatology, 2017; 134-141.
MARTINEZ R, et al. Anatomia das Glândulas Anexas. Sistema digestório: integração básico-clínica. São Paulo: Blucher, 2016; p. 89-106.
MONTERO-OLEAS N, et al. Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews. BMC complementary medicine and therapies, 2020; p. 1-15.
PACÍFICO FA, et al. Vias biliares extra-hepáticas e trígono cistohepático: estudo anatomotopográfico. Anais da Faculdade de Medicina de Olinda, 2022; p. 21–24.
PALLADINI MC. Indicações para o uso de canabinoides. Brazilian Journal of Pain, 2023; supl. 2.
SANTOS AA, LIMA JMC. Fisiologia Hepática. Sistema digestório: integração básico-clínica, 2016; p. 575-602.
SILVA RAMOS N, et al. PERFIL DE BIOMARCADORES HEPÁTICOS E SUA RELAÇÃO COM A ESTEATOSE HEPÁTICA. Revista Foco (Interdisciplinary Studies Journal), 2023; n. 11.
SILVESTRI C, et al. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Journal of hepatology, 2015; p. 1382-1390.
VASCONCELOS DCAD, et al. SÍNDROME METABÓLICA E SEUS CUIDADOS DENTRO DA ENDOCRINOLOGIA. Periódicos Brasil. Pesquisa Científica, 2025; p. 2484-2495.
VESKOVIĆ M, et al. A interconexão entre a resistência à insulina hepática e a doença hepática esteatótica associada à disfunção metabólica — a transição de uma abordagem adipocêntrica para uma abordagem centrada no fígado. Edições atuais Mol. Biol., 2023; 9084-9102.
WEBER LD, BLAU TCC. PRINCIPAIS LESÕES ENCONTRADAS EM FÍGADO DE BOVINOS EM UM ABATEDOURO FRIGORÍFICO DA REGIÃO OESTE DO PARANÁ. Arquivos Brasileiros de Medicina Veterinária FAG, 2018; n. 2.
XIE R, LIU M. Relationship between non-alcoholic fatty liver disease and degree of hepatic steatosis and bone mineral density. Frontiers in Endocrinology, 2022; p. 857110.
YANG L, et al. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radical Biology and Medicine, 2014; p. 260-267.